Satellos Bioscience Inc. to Present Game-Changing Science at Next European Molecular Biology Organization Workshop

Ryan Mitchell, PhD and Director of Business Development, will showcase advances in Satellos’ new muscle regeneration technology on April 25-26 in Gouvieux, France

Toronto, Ontario–(Newsfile Corp. – April 21, 2022) – Satellos Bioscience Inc. (TSXV:MSCL) (“satellites“or the”society“), a regenerative medicine company focused on developing therapies that change the way degenerative muscle diseases are treated, is pleased to announce that Ryan Mitchell, PhD and Director of Business Development will be presenting a poster on the groundbreaking science of Satellos at of an upcoming European conference Molecular Biology Organization (EMBO) Workshop on Muscle Formation, Maintenance, Regeneration and Pathology The workshop will take place in Gouvieux, France, April 24-29, 2022.

During the workshop, Dr. Mitchell will present a poster on Satellos’ unique and proprietary work in skeletal muscle regeneration and the company’s progress in inventing and developing drugs that reset the innate ability of the body to repair itself. At the center of the presentation will be an update on Satellos’ lead drug program focused on treating Duchenne, a fatal genetic disease with insufficient treatment options.

“EMBO is one of the most prestigious life science organizations on the planet, and we are thrilled to have Ryan showcase our transformational work in this highly regarded workshop,” said Frank Gleeson, Founder and CEO of Satellites. “At Satellos, we are developing an entirely new class of drugs that aim to restore the innate process of muscle repair and regeneration in people with Duchenne and a range of other dystrophies. We are excited to share our science and our developments with the many leading experts in skeletal muscle development, homeostasis, regeneration and pathology who will participate in this premier forum.”

About Duchenne

Duchenne is a fatal genetic disease that slowly and progressively robs people of muscle strength and function. Diagnosed in childhood, affecting approximately 1 in 5,000 live male births, Duchenne is caused by a change in the dystrophin gene. Dr. Michael Rudnicki discovered that muscle stem cells in people living with Duchenne are severely compromised in their ability to create the muscle progenitor cells upon which repair and regeneration depend. As a result, the muscles of Duchenne patients are unable to cope with the continuous damage that accumulates throughout life, becoming progressively more damaged. No treatment exists today to correct this situation.

About Satellos Bioscience Inc.

Satellos is a biotechnology company dedicated to the development of life-changing drugs to treat degenerative muscle conditions. Our scientists have discovered what we believe is a previously unknown root cause of skeletal muscle degeneration. One that has the potential to transform the way muscle disorders are treated. Our Scientific Founder, Dr. Michael Rudnicki, is a thought leader who discovered and demonstrated how muscle stem cells regulate muscle repair and growth throughout life. He showed how defects in a process known as stem cell “polarity”, which controls how muscle stem cells divide to create muscle progenitor cells, lead to failure of muscle regeneration in Duchenne and potentially to other muscle disorders. Because of this continued inability to produce sufficient numbers of new muscle cells, the muscles of people living with Duchenne are unable to keep up with and repair the continuous and cumulative damage to their muscles. Satellos’ core program is focused on the development of an oral therapeutic drug (i.e. a pill) to correct muscle stem cell polarity and restore the body’s innate muscle repair and regeneration process. . We believe that our unique therapeutic approach represents a potential modifying treatment for Duchenne disease and other dystrophies, offering new hope to patients. To extend our programs to other degenerative muscle conditions or disorders, Satellos has created a proprietary discovery platform, MyoReGenX™, which we use to identify pathological situations in which muscle stem cell polarity and regeneration deficits occur and amenable to therapeutic treatment. For more information or to discuss potential collaborations with Satellos regarding our discovery platform and therapeutic candidates or our subsidiary Amphotericin B Technologies Inc., please contact Ryan Mitchell, PhD, Director – Business Development at rmitchell@satellos.com or visit Satellites.com.

CONTACTS:

Christina Cameron
Investor Relations
Satellos Bioscience Inc.
ccameron@satellos.com
647.660.1780

Notice Regarding Forward-Looking Statements:

This press release contains forward-looking information or forward-looking statements within the meaning of Canadian and United States securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the anticipated benefits of modulation of stem cell polarity. ; its prospective impact on Duchenne patients and muscle regeneration in general; the projected benefits of Satellos’ therapeutic approach, including small molecule drug candidates; Satellos’ technologies and drug development plans; the timeline for commencing human clinical trials; the anticipated progress of Satellos’ research and development; and Company priorities and planned achievement of drug molecule evaluation milestones and plans. All statements that are, or information that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, goals, assumptions, expectations or beliefs, are “forward-looking information or statements”. Often, but not always, forward-looking information or statements can be identified by the use of words such as “progress”, “target”, “plan”, “expect”, “intend”, “anticipate”. “, “estimate”, “believe”, “hope”, “target”, “potentially”, “eventually”, “ongoing efforts”, “develop”, “pioneer”, “groundbreaking”, “milestone”, “more away”, “outlook” or any variation (including negative variations) of these words and phrases, or state that certain actions, events or results “might”, “might”, “could”, “could” or “would” to be taken, to occur, to lead to, to cause or to be reached. These statements are based on the Company’s management’s current expectations and views of future events. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and may differ materially due to known and unknown risk factors and uncertainties affecting the Company, including risks related to the pharmaceutical and bioscience industry, general market and stock markets. , economic factors and management’s ability to manage and operate the business of the Company generally. Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in the forward-looking statements, there may be other factors that cause actual actions, events or results differ from those anticipated, estimated or expected. . Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date they are made, and Satellos undertakes no obligation to publicly update or revise any forward-looking statement, whether either as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Do not distribute in the United States

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/121033

Leave a Comment